Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours.

ABSTRACT:

Introduction

Phosphorylated Akt (P-Akt) is an attractive molecular target because it contributes to the development of breast cancer and confers resistance to conventional therapies. Akt also serves as a signalling intermediate for receptors such as human epidermal growth factor receptor (HER)-2, which is overexpressed in 30% of breast cancers; therefore, inhibitors to this pathway are being sought. New celecoxib analogues reportedly inhibit P-Akt in prostate cancer cells. We therefore examined the potential of these compounds in the treatment of breast cancer. The analogues were characterized in MDA-MB-453 cells because they overexpress HER-2 and have very high levels of P-Akt.

Methods

To evaluate the effect of the celecoxib analogues, immunoblotting was used to identify ch

SUBMITTER: Kucab JE 

PROVIDER: S-EPMC1242152 | biostudies-literature | 2005

REPOSITORIES: biostudies-literature